Impact of Atorvastatin on Prostate Cancer Progression During ADT

Summary

This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.

Conditions

• Metastatic Prostate Cancer
• Recurrent Prostate Cancer

Interventions

DRUG

Atorvastatin 80mg

Capsules including 80 mg of atorvastatin

DRUG

Placebo oral capsule

Similar capsules as in the atorvastatin arm, but without the active ingredient

Sponsors & Collaborators

• Turku University Hospital

  collaborator OTHER_GOV

• Central Finland Hospital District

  collaborator OTHER

• Tartu University Hospital

  collaborator OTHER

• University of Aarhus

  collaborator OTHER

• Fimlab laboratories

  collaborator UNKNOWN

• Helsinki University Central Hospital

  collaborator OTHER

• Kuopio University Hospital

  collaborator OTHER

• Oulu University Hospital

  collaborator OTHER

• Seinajoki Central Hospital

  collaborator OTHER

• The Hospital of Vestfold

  collaborator OTHER

• Telemark Hospital Trust

  collaborator UNKNOWN

• Tampere University Hospital

  lead OTHER

Principal Investigators

• Teemu Murtola, MD, PhD · Tampere University Hospital

• Otto Ettala, MD, PhD · Turku University Hospital

• Heikki Seikkula · Central Finland Central Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-08-15

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• Denmark
• Estonia
• Finland
• Norway

Study Locations